Vernakalant

Aug 28, 2018

Correvio to Participate in Upcoming Investor Conferences

Aug 16, 2018

Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients

Aug 14, 2018

Correvio Announces Brinavess® Selected as Potentially Eligible for Priority Review in China

Aug 07, 2018

Correvio To Report Second Quarter 2018 Financial Results On August 14, 2018

Jun 11, 2018

Correvio Provides U.S. Regulatory Update for BRINAVESS

May 17, 2018

Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess® in China

Apr 26, 2018

Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference

Apr 17, 2018

Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®

Mar 28, 2018

Cardiome Announces Recent Insider Purchases

Feb 08, 2018

Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference

Jan 10, 2018

Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit

Nov 02, 2017

Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®

Aug 21, 2017

Cardiome Provides U.S. Regulatory Update For BRINAVESS

Jun 12, 2017

Cardiome Announces Commercial Launch of BRINAVESS® (Vernakalant Hydrochloride) in Canada